Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis

Pediatric Blood and Cancer

Volumn 60, Issue 7, 2013, Pages 1148-1153

  Narayanan, Karthik R ^a   Bansal, Deepak ^a   Walia, Rama ^a   Sachdeva, Naresh ^a   Bhansali, Anil ^a   Varma, Neelam ^a   Marwaha, R K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

FSH; LH; Puberty; Sexual maturity rating; Stunting; Tanners scale; Thyroid function tests; TKI

Indexed keywords

CLONIDINE; GROWTH HORMONE; IMATINIB; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADOLESCENT; ANTHROPOMETRY; ARTICLE; BODY HEIGHT; BONE AGE; CHILD; CHILD GROWTH; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; GROWTH HORMONE DEFICIENCY; GROWTH RETARDATION; HORMONE DETERMINATION; HUMAN; INSULIN TOLERANCE TEST; MALE; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROVOCATION TEST; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ANTHROPOMETRY; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRIMIDINES;

EID: 84878255303     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24397     Document Type: Article

References (27)

1. Kolb EA, Pan Q, Ladanyi M, et al. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood. Cancer 2003; 98: 2643-2650.
2. Andolina JR, Neudorf SM, Corey SJ. How I treat childhood CML. Blood 2012; 119: 1821-1830.
3. Barr RD. Imatinib mesylate in children and adolescents with cancer. Pediatr Blood Cancer 2010; 55: 18-25.
4. Millot F, Baruchel A, Guilhot J, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial. J Clin Oncol 2011; 29: 2827-2832.
5. Shima H, Tokuyama M, Tanizawa A, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 2011; 159: 676-681.
6. Bansal D, Shava U, Varma N, et al. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer 2012; 59: 481-484.
7. Mariani S, Giona F, Basciani S, et al. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet 2008; 372: 111-112.
8. Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. Int J Hematol 2009; 89: 251-252.
9. Vandyke K, Dewar AL, Fitter S, et al. Imatinib mesylate causes growth plate closure in vivo. Leukemia 2009; 23: 2155-2159.
10. Schmid H, Jaeger BA, Lohse J, et al. Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib. Haematologica 2009; 94: 1177-1179.
11. Rastogi MV, Stork L, Druker B, et al. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. Pediatr Blood Cancer 2012; 59: 840-845.
12. Hobernicht SL, Schweiger B, Zeitler P, et al. Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy. Pediatr Blood Cancer 2011; 56: 671-673.
13. who.int [homepage on the internet]. WHO: Growth reference data for 5-19 years, 2007. Available from http://www.who.int/growthref/en/
14. who.int [homepage on the internet]. WHO AnthroPlus for personal computers: Software for assessing growth of the world's children and adolescents. Geneva: WHO, 2009. Available from http://www.who.int/growthref/tools/en/
15. Cohen P, Rogol AD, Deal CL, et al. 2007 ISS Consensus Workshop participants. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: A summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008; 93: 4210-4217.
16. who.int [homepage on the internet]. WHO: Growth reference data for 5-19 years: BMI-for-age (5-19 years), 2007. Available from http://www.who.int/growthref/who2007_bmi_for_age/en/index.html
17. Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: Relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994; 78: 744-752.
18. Juul A, Dalgaard P, Blum WF, et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: The relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995; 80: 2534-2542.
19. Bajpai A, Menon PS. Insulin like growth factors axis and growth disorders. Indian J Pediatr 2006; 73: 67-71.
20. Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: An emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009; 6: 219-228.
21. De Groot JW, Zonnenberg BA, Plukker JT, et al. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 2005; 78: 433-438.
22. Patil ST, Parchand MP, Meshram MM, Kamdi NY. Applicability of Greulich and Pyle skeletal age standards to Indian children. Forensic Sci Int 2012; 216: 200.e1-200.e4.
23. Kebapcilar L, Bilgir O, Alacacioglu I, et al. Does imatinib mesylate therapy cause growth hormone deficiency? Med Princ Pract 2009; 18: 360-363.
24. Elizabeth KE. Nutrition and child development, 4th edition. Hyderabad: Paras; 2010.
25. Bjarnason R, Savage M. Growth hormone insensitivity: A widening diagnosis. Arch Dis Child 1999; 81: 378-379.
26. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354: 2006-2013.
27. O'Sullivan S, Horne A, Wattie D, et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 2009; 94: 1131-1136.